Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fixed CIP and SIP Devices – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fixed CIP and SIP Devices market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Fixed CIP and SIP Devices was estimated to be worth US1,942millionin2025andisprojectedtoreachUS1,942millionin2025andisprojectedtoreachUS 3,039 million, growing at a CAGR of 6.7% from 2026 to 2032. In 2024, global sales of fixed CIP and SIP devices reached 35,000 units, with an average selling price of approximately US$ 55,500 per unit. These automated cleaning and sterilization devices are widely used in the pharmaceutical (drug product manufacturing, sterile injectables, oral solid dosage, API synthesis), biotechnology (mAb production, cell culture, vaccine manufacturing, gene therapy, fermentation), food and beverage (dairy, brewing, soft drinks, juice, liquid eggs, sauces, confectionery), and chemical (specialty, fine, cosmetic) industries. Through fixed integration of pipes and tanks (hard-piped to bioreactors, fermenters, mixing vessels, filling lines, storage tanks, heat exchangers, centrifuges, homogenizers, and process piping loops), they enable in-line cleaning and sterilization of production equipment without disassembly, ensuring production continuity (24/7 operations for biopharma blockbuster drugs, high-volume dairy/beverage filling), hygiene compliance (cGMP, FDA, EU GMP Annex 1, FSMA Preventive Controls for Human Food, SQF, BRCGS, IFS, GFSI benchmarked standards, HACCP), and product quality stability (batch-to-batch reproducibility, no cross-contamination between products, allergen changeover confidence for food production, sterile drug product sterility assurance level 10⁻⁶ for terminally sterilized products, aseptic processing, contamination control strategy CCS) while effectively reducing labor costs (by 70-85% compared to manual disassembly/cleaning/reassembly) and cross-contamination risks (dedicated piping for each product type, CIP return lines segregated, SIP steam barriers between zones, double-seat mixproof valves preventing cross-contamination between CIP supply and product). Upstream raw materials include stainless steel sheets and pipes (304/316L, electropolished surfaces Ra <0.5μm for biopharma WFI systems and ultrapure water loops), high-performance pumps and valves (centrifugal pumps, positive displacement pumps, diaphragm valves, mixproof valves, air-operated valves, sanitary butterfly valves, all with ASME BPE certification), steam generators (clean steam generators, pure steam generators for SIP, pharmaceutical grade, 316L wetted parts, non-pyrogenic, conductivity <1.3 µS/cm), control modules (PLC, DCS, SCADA, HMI, batch management systems, Rockwell Automation PlantPAx, Siemens Simatic PCS 7, Emerson DeltaV, ABB 800xA, Yokogawa CENTUM), and sensors (conductivity, temperature, pressure, flow, pH, turbidity, dissolved oxygen for cleaning validation). Major suppliers include Baosteel, POSCO, Outokumpu (stainless steel), Emerson (Rosemount sensors), Siemens (automation, drives), Endress+Hauser (instrumentation), Alfa Laval (pumps, valves), GEA Group (process equipment), SPX FLOW (pumps). Downstream customers include pharmaceutical companies such as Pfizer, Roche, Sanofi, Novartis, Merck, Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, AstraZeneca, GSK; food and beverage companies such as Nestlé, Danone, PepsiCo, Coca-Cola, Unilever, Kraft Heinz, Mars, AB InBev, Heineken; and CDMOs (contract development and manufacturing organizations) such as Samsung BioLogics, Lonza, WuXi Biologics, Catalent, Thermo Fisher Patheon, Recipharm, Siegfried, Curia. In the future, fixed CIP and SIP devices will develop towards intelligence (digital twins of CIP/SIP circuits for predictive cleaning validation, AI-driven optimization of cleaning cycles based on real-time soil load sensors, remote operation, and maintenance via IIoT dashboards, condition monitoring of spray devices/pressure drops, rotating spray balls, static spray nozzles), high efficiency and energy saving (reduced consumption of cleaning fluids (caustic soda NaOH, nitric/phosphoric acid, or formulated CIP detergents), rinse water (recovery systems, reuse of final rinse as initial pre-rinse for next batch, cascade rinsing, saving 20-40% water and chemical usage, reduced steam demand for SIP with shorter cycle times, heat exchangers for heat recovery from waste streams, condensate return, better insulation of steam lines, reduced idle steam losses), modular expansion (skid-mounted, pre-validated modules added as production capacity scales, additional bioreactors, fill lines, tanks, with standardized connections for reduced site integration time and lower validation burden), and compliance with global GMP (EU GMP Annex 1 2025 addendum requiring contamination control strategy, documented CCS, FDA 21 CFR Part 211, WHO TRS 961, ICH Q7), HACCP (Hazard Analysis and Critical Control Points for food safety, allergen management, cleaning verification frequency based on risk assessment, preventive controls for cross-contact) standards. Moreover, the fixed segment will maintain steady growth against the backdrop of upgrading of the pharmaceutical and high-end food processing industries (70% of global biologics manufacturing capacity is built with fixed CIP/SIP systems at large-scale facilities, 40% of large dairy/brewing operations use fixed CIP for main processing lines) requiring validated, high-throughput, automated, energy-and-water efficient CIP/SIP for 24/7 continuous manufacturing, as opposed to mobile units on casters for multi-product campaign manufacturing.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/6097795/fixed-cip-and-sip-devices
1. Executive Summary: Addressing Core User Needs in Hard-Piped Hygienic Processing
Biopharmaceutical plant engineers, food safety compliance officers, and pharmaceutical validation specialists face three persistent challenges: integrating hard-piped cleaning with existing process equipment (bioreactors, mixing tanks, filling lines) without compromising sanitary design (dead legs minimized, sloped piping for drainability, break tanks, air gaps, avoid cross-contamination risk during concurrent manufacture), achieving validated steam sterilization (SIP cycle parameters: 121-134°C (usually 121°C for 15-30 minutes, 134°C for 3-5 minutes for terminal sterilization, load sensors, thermocouples at cold spots, heat distribution mapping, empty chamber and loaded chamber validation, biological indicators, Geobacillus stearothermophilus spores for steam sterilization validation), and reducing water and chemical consumption (fixed systems, larger pipe volumes, longer piping runs, larger tanks, more rinse stages needed).
The fixed CIP/SIP device—available as single-use system (disposable flow paths, single product campaign, no cleaning validation, best for multi-product, small-batch clinical/commercial, eliminates cross-contamination risk, no CIP/SIP hardware for product contact parts) and multi-purpose system (shared fixed piping, cleanable/steamable between products or batches, two or more product campaigns, larger-volume production, capital cost spread over product lines, changeover cleaning and sterilization validation required for each product change) —provides permanent hard-piped integration (return to return or supply/return loops, distribution rings, spray devices (static spray balls, rotating spray heads, pigging systems) for large process equipment and long pipe runs, central CIP supply station feeding multiple downstream vessels (recirculation of cleaning fluids through supply/return headers), allowing sequence, cascade, parallel cleaning, maximum automation (<2 minutes operator intervention per batch). Global industry growth drivers in H1 2026 include large-scale biologics capacity expansion (new 15,000-20,000L single-use bioreactors increasingly single-use assembly not cleaned/fixed units, while stainless steel bioreactors >10,000L require fixed CIP/SIP, 35% of new biomanufacturing capacity is stainless steel large-scale, 65% single-use), regulatory enforcement of EU GMP Annex 1 Contamination Control Strategy, and food industry automation (CIP/SIP for aseptic filling of ESL and shelf-stable beverages, dairy, liquid egg, sauces, minimizing changeover downtime).
2. Segment Analysis: Single-Use vs. Multi-Purpose Systems
Single-Use System (35% of 2025 revenue, growing at 8.5% CAGR – fastest-growing):
- Description: Disposable, pre-sterilized flow paths: bags, tubing, connectors, manifolds, mixing assemblies, bioreactor liners. No cleaning validation (no carryover). Gamma irradiated. Lower capital.
- Applications: Multi-product biopharma, clinical/commercial small-batch CMO, gene therapy, cell therapy, personalized medicine, high-potency APIs.
- Advantages: No CIP/SIP (no water, steam, chemicals, cleaning validation labor). Lower capital, faster changeover (<2 hr to replace disposable set). Reduced cross-contamination risk.
- Challenge: Higher consumable cost per batch ($3,000-20,000). Plastic waste stream. Limited scale (currently ≤3,000L disposable bioreactors for cell culture; larger SS 20,000L fixed).
Multi-Purpose (Shared) System (58% of 2025 revenue, growing at 6.0% CAGR – largest segment):
- Description: Fixed stainless steel piping and vessels (10,000-25,000L). Cleaned/sterilized between batches (CIP/SIP). Suitable high-volume (>10 batches per year) same product or validated changeover cleaning for multiple products.
- Applications: Large-scale commercial mAbs, vaccines, insulin, dairy processing, high-volume food.
- Advantages: Lowest per-unit cost at scale. Durable 20+ year. Automated.
- Challenge: High capital. Validation for product changeover. Risk carryover if cleaning not validated.
Others (7%): Hybrid, single-use + fixed, custom.
Industry Vertical Insight (Biopharma vs. Food vs. CDMO):
Biopharma mix single-use (clinical, multi-product CMO, gene/cell therapy, mAb, early-stage). Food multi-purpose (dairy, beverage, liquid, high-volume). CDMO (multi-client) single-use (changeover speed, lower capital).
3. Competitive Landscape & Exclusive Observations
Global Leaders (process hygienic & pharma specialists):
- INOXPA (Spain): 18% share, food/dairy/pharma fixed CIP. H1 2026: $350 million (+6% YoY).
- Propack Technologies, Puretech Systems Limited, PANACEAEE, Bhagwati Pharma, IUS Equipment, Technsys, Pharmalab India Pvt.Ltd, BiOZEEN: regional.
Exclusive Observation (June 2026): ”Digital twin” for CIP/SIP circuit validation (virtual modeling of fluid dynamics, thermal distribution, cleaning coverage). Saves 30% validation hours, faster installation.
4. Regional Outlook & Forecast Adjustments (2026–2032)
- Asia-Pacific (largest, 48% share): CAGR 7.2% (China biopharma capacity, India pharmaceutical manufacturing, Korea/Singapore CDMO).
- North America: CAGR 6.5% (US biopharma, food automation, EU GMP alignment).
- Europe: CAGR 6.0% (Western Europe pharma, Eastern Europe food/pharma).
5. Strategic Recommendations
- For large-scale biopharma (>10,000L stainless steel, commercial blockbuster mAbs, high-volume): Multi-purpose fixed (lowest unit cost, highest automation). New Annex 1 CCS validation. Digital twin for FAT/SAT.
- For multi-product CDMO/CMO (early-phase, commercial clinical supply, high changeover, personalized medicine): Single-use (eliminate cleaning validation, reduce changeover). Contract commitment, plastic burden.
- For fixed CIP/SIP manufacturers: Digital twin (virtual validation, simulation). Low-water rinsing (25-35% reduction). Pre-validated modular blocks.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
